Find your next paid study

St. Jude Children's Research HospitalNCT07052370

~$500 – $7,500

Actual pay is set by the research site.

LeukemiaAcute Myeloid Leukemia in RemissionMyelodysplasia+10 more

Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha/Beta T-Cell and B-Cell Depletion for Patients With Hematologic Malignancies With Targeted ATG Dosing Pilot Study, IDE 13641

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs…

Actual pay is set by the research site.

Hematologic MalignancyMyelodysplastic SyndromesAcute Myeloid Leukemia+1 more

A Pilot Study of Home Blood Transfusions for Patient With Cancer Who Have Transfusion Dependent Cytopenias

This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic …

Thomas Jefferson UniversityNCT07121140

Actual pay is set by the research site.

Phase 1

A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractor…

Multiple Myeloma in RelapseMyeloma MultipleMultiple Myeloma Progression+11 more

Kelonia Therapeutics, Inc.

~$150 – $4,200

Actual pay is set by the research site.

Phase 1

A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies

This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase…

Relapsed/Refractory Hematological MalignanciesRelapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLLRelapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)+4 more

Beta Lactam Allergy in Patients With a Hematologic Malignancy

~$150 – $4,200

Actual pay is set by the research site.

Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy

The goal of this RENEW-EVAL project is to understand the potential barriers to implementation of the RENEW intervention into the routine clinical care of patie…

Abramson Cancer Center at Penn MedicineNCT06967467

Actual pay is set by the research site.

Multiple MyelomaRelapsed Hematologic Malignancy

Evaluating Patient-Reported Outcomes and Wearable Data Among Individuals With Relapsed/Refractory Multiple Myeloma

This study will evaluate the feasibility of a digital health coaching program for adults with relapsed or refractory multiple myeloma (R/R MM). One hundred adu…

Pediatric CancersHematologic MalignanciesSolid Tumors

~$10 – $1,125

Actual pay is set by the research site.

Pack HealthNCT05956457

Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

Background: \- Gene therapy involves changing the genes inside the body s cells to stop disease. It is very closely regulated. People who have had this therap…

National Cancer Institute (NCI)NCT02315599

~$10 – $675

Actual pay is set by the research site.

A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies

This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the …

Hematologic Malignancy

Northside Hospital, Inc.NCT05417971

Actual pay is set by the research site.

Phase 2

A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patien…

Advanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)+1 more

Cogent Biosciences, Inc.NCT04996875

~$75 – $2,800

Actual pay is set by the research site.

Hematopoietic Stem Cell TransplantationHematologic Malignancy

αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT) for Children and Young Adults With Hematologic Malignancies

This is a study utilizing the Magnetic-activated cell sorting (CliniMACS®) Alpha-Beta T-cell (αβT)/Cluster of Differentiation 19 (CD19), also called B lymphocy…

Nationwide Children's HospitalNCT06082947

Actual pay is set by the research site.

Hematologic MalignancySolid TumorSickle Cell Disease+3 more

Let's Get REAL: A Pilot Trial of a Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy

The investigators will conduct a pilot feasibility and efficacy trial of a newly developed family health communication tool (called Let's Get REAL) in increasi…